Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.27, Zacks reports. Astellas Pharma had a net margin of 13.66% and a return on equity of 23.54%.
Astellas Pharma Stock Performance
ALPMY traded up $0.30 during trading on Wednesday, hitting $14.11. 34,902 shares of the company traded hands, compared to its average volume of 169,851. The firm has a market cap of $25.53 billion, a P/E ratio of 13.13 and a beta of 0.08. The stock’s fifty day moving average is $13.41 and its 200 day moving average is $14.63. The company has a quick ratio of 0.90, a current ratio of 1.17 and a debt-to-equity ratio of 0.17. Astellas Pharma has a one year low of $10.03 and a one year high of $17.35.
Analysts Set New Price Targets
Separately, Zacks Research cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold”.
Astellas Pharma Company Profile
Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.
Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).
Featured Stories
- Five stocks we like better than Astellas Pharma
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
- AMD’s Post-Earnings Drop May Be the Opportunity Investors Wanted
- 3 Stocks That Prove the AI Trade Isn’t Over, It Moved
- The FTC Is Suing Hims & Hers Health—Here’s Why Investors Shouldn’t Panic
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
